Condition: Hepatocellular Carcinoma · Sponsor: Anwaar Saeed
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).
This description comes directly from the study's public registry record.
Debra Diecks · 4126238364 · diecksda@upmc.edu
Always discuss trial participation with your own doctor first.
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Houston Methodist Neal Cancer Center | Houston, Texas, United States | Not Yet Recruiting |
| Mays Cancer Center, UT Health San Antonio | San Antonio, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06698250